甘李药业股份有限公司2025年第一次临时股东大会决议公告

Core Points - The first extraordinary general meeting of shareholders for 2025 was held on November 17, 2025, at the company's conference room in Tongzhou District, Beijing [2] - All resolutions proposed during the meeting were approved without any dissenting votes [2][4] - The meeting was legally convened and conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association [2][7] Meeting Attendance - The meeting was chaired by the company's chairman, Mr. Chen Wei, with the attendance of all current directors and supervisors [2][3] - The company secretary and other senior executives were also present at the meeting [3] Resolutions Reviewed - The resolution to cancel the supervisory board and amend the articles of association was passed with more than two-thirds of the voting rights [4][6] - Several governance documents were revised and approved, including rules for shareholder meetings, board meetings, external guarantee systems, investment management methods, and related party transaction management [5][6] - A new remuneration management method for directors and senior management was established and approved [5][6] Legal Verification - The meeting was witnessed by lawyers from Zhonglun Law Firm, who confirmed that all procedures and resolutions complied with legal and regulatory requirements [7] Board Changes - Non-independent director Mr. Xu Fuming submitted his resignation due to adjustments in the company's governance structure, effective immediately upon receipt by the board [9][11] - Mr. Xu will continue to hold other positions within the company [9][11] - A new employee representative director was elected during the employee representative meeting held on November 17, 2025, following the approval of the supervisory board cancellation [12]